AVROBIO, Inc. (AVRO) Shows Promising Potential in Gene Therapy with Recent Developments
AVROBIO, Inc. (AVRO), a leading gene therapy company, closed at $1.24 in after-hours trading on Tuesday, reflecting a 13.76% increase. While there are no specific reasons for the surge or any latest news, recent developments and financial data provide valuable insights into the company’s prospects. Positive Milestone in Cystinosis Treatment AVROBIO made headlines on May […]
